Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Tiziana Life Sciences Ltd - Common Shares (NQ:TLSA)

1.000 +0.026 (+2.64%)

Streaming Delayed Price Updated: 4:00 PM EDT, Aug 7, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	981,118
Open	0.9880
Bid (Size)	0.9627 (3,000)
Ask (Size)	0.9949 (300)
Prev. Close	0.9743
Today's Range	0.9564 - 1.030
52wk Range	0.8663 - 2.530
Shares Outstanding	194,612,289
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer

August 06, 2026

From Tiziana Life Sciences Ltd.

Via GlobeNewswire

Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer

August 04, 2026

From Tiziana Life Sciences Ltd.

Via GlobeNewswire

Performance

YTD	-37.5%	-37.5%
1 Month	-20.6%	-20.6%
3 Month	-33.8%	-33.8%
6 Month	-21.3%	-21.3%
1 Year	-57.1%	-57.1%

More News

Tiziana Reports Reduction in Brain Inflammation in Third Multiple System Atrophy Patient Treated with Intranasal Foralumab

July 31, 2026

From Tiziana Life Sciences Ltd.

Via GlobeNewswire

Tiziana Life Sciences Announces Purchase of Shares by Executive Chairman

July 22, 2026

From Tiziana Life Sciences Ltd.

Via GlobeNewswire

Tiziana Announces Last Patient Successfully Dosed in its Phase 2 INFORM-MS Trial

June 25, 2026

From Tiziana Life Sciences Ltd.

Via GlobeNewswire

Tiziana Life Sciences Announces Purchase of Shares by Executive Chairman

June 15, 2026

From Tiziana Life Sciences Ltd.

Via GlobeNewswire

Innoviva Stock Is Up Just 10% This Past Year. Here's Why a Fund Bought $2.5 Million More ↗

May 29, 2026

Via The Motley Fool

Tiziana Life Sciences to Present at the Jefferies Global Healthcare Conference in New York

May 28, 2026

From Tiziana Life Sciences Ltd.

Via GlobeNewswire

Tiziana Fully Enrolls its Phase 2 Placebo Controlled Multiple Sclerosis Trial

May 21, 2026

From Tiziana Life Sciences Ltd.

Via GlobeNewswire

Tiziana Announces New Positive Clinical Data for Intranasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis

May 19, 2026

From Tiziana Life Sciences Ltd.

Via GlobeNewswire

Tiziana Reports Reduced Brain Inflammation in Multiple System Atrophy Patients Treated with Intranasal Foralumab

May 14, 2026

From Tiziana Life Sciences Ltd.

Via GlobeNewswire

Tiziana Life Sciences Announces Publication of Positive Data Demonstrating Intranasal Anti-CD3 Antibody Attenuates Long COVID Neuroinflammation and Improves Cognitive Function

April 16, 2026

From Tiziana Life Sciences Ltd.

Via GlobeNewswire

Tiziana Life Sciences Announces Late Breaking Poster Accepted for Presentation at the 7th World Parkinson Congress

April 14, 2026

From Tiziana Life Sciences Ltd.

Via GlobeNewswire

Tiziana Announces Data Showing Nasal Anti-CD3 Improves Cognition Associated with Aging

April 01, 2026

From Tiziana Life Sciences Ltd.

Via GlobeNewswire

Tiziana Life Sciences Announces New Biomarker Data Showing Nasal Foralumab Downregulates CSF Inflammation, Upregulates Neuroprotective Pathways, and Correlates with Reduced Microglial Activation on PET Scans in na-SPMS Patients with PIRA

February 25, 2026

From Tiziana Life Sciences Ltd.

Via GlobeNewswire

Tiziana Life Sciences Announces the Peer-Reviewed Publication of Clinical Study Results for Intranasal Foralumab

January 20, 2026

From Tiziana Life Sciences Ltd.

Via GlobeNewswire

Tiziana Life Sciences Announces Closing of Oversubscribed $8.8 Million Registered Direct Offering of Ordinary Shares

January 16, 2026

From Tiziana Life Sciences Ltd.

Via GlobeNewswire

Tiziana Life Sciences Announces Registered Direct Offering of up to approximately $17.6 Million

January 16, 2026

From Tiziana Life Sciences Ltd.

Via GlobeNewswire

Tiziana Life Sciences to Present at the 9th Annual Neuroscience Innovation Forum During J.P. Morgan Healthcare Conference Week in San Francisco

January 09, 2026

From Tiziana Life Sciences Ltd.

Via GlobeNewswire

Tiziana Files Annual Safety Report for Intranasal Foralumab with FDA

December 29, 2025

From Tiziana Life Sciences Ltd.

Via GlobeNewswire

Tiziana Life Sciences Announces Acquisition of Shares by Executive Chairman

December 19, 2025

From Tiziana Life Sciences Ltd.

Via GlobeNewswire

Tiziana Life Sciences to Ring the Closing Bell at Nasdaq

December 17, 2025

From Tiziana Life Sciences Ltd.

Via GlobeNewswire

Tiziana Life Sciences Doses First Patient in Phase 2 Alzheimer’s Clinical Trial

December 17, 2025

From Tiziana Life Sciences Ltd.

Via GlobeNewswire

Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer

December 15, 2025

From Tiziana Life Sciences Ltd.

Via GlobeNewswire

Tiziana Life Sciences Announces Withdrawal of Proposed Public Offering

December 15, 2025

From Tiziana Life Sciences Ltd.

Via GlobeNewswire

Frequently Asked Questions

Is Tiziana Life Sciences Ltd - Common Shares publicly traded?

Yes, Tiziana Life Sciences Ltd - Common Shares is publicly traded.

What exchange does Tiziana Life Sciences Ltd - Common Shares trade on?

Tiziana Life Sciences Ltd - Common Shares trades on the Nasdaq Stock Market

What is the ticker symbol for Tiziana Life Sciences Ltd - Common Shares?

The ticker symbol for Tiziana Life Sciences Ltd - Common Shares is TLSA on the Nasdaq Stock Market

What is the current price of Tiziana Life Sciences Ltd - Common Shares?

The current price of Tiziana Life Sciences Ltd - Common Shares is 1.000

When was Tiziana Life Sciences Ltd - Common Shares last traded?

The last trade of Tiziana Life Sciences Ltd - Common Shares was at 08/07/26 04:00 PM ET

What is the market capitalization of Tiziana Life Sciences Ltd - Common Shares?

The market capitalization of Tiziana Life Sciences Ltd - Common Shares is 194.61M

How many shares of Tiziana Life Sciences Ltd - Common Shares are outstanding?

Tiziana Life Sciences Ltd - Common Shares has 195M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.